Table 2.

Somatic mutations associated with clinical outcomes in the current prognostic systems for MDS

MutationBernard et al, IPSS-M68 
Leukemia-free survival
N = 2428
Bersanelli et al64 survival
N = 2043
Nazha et al65 survival N = 479
Incidence, %Hazard ratio 
TP53multi-hit 11 3.27 +  +  
MLLPTD 2.22   
FLTITD+TKD 2.22 +§   
SF3B15q 1.66 +   
NPM1 1.54 +§   
RUNX1 16 1.53 + + 
NRAS 1.52 + + 
ETV6 1.48   
IDH2 1.46 +  
CBL 1.34 + + 
EZH2 1.31 + + 
U2AF1 11 1.28 +   
SRSF2 18 1.27 +#  + 
DNMT3A 19 1.25 +  
ASXL1 30 1.24 + + 
KRAS 1.22  + 
SF3B1α 28 0.92 + + 
STAG2    +∗∗  
RAD21    + 
MutationBernard et al, IPSS-M68 
Leukemia-free survival
N = 2428
Bersanelli et al64 survival
N = 2043
Nazha et al65 survival N = 479
Incidence, %Hazard ratio 
TP53multi-hit 11 3.27 +  +  
MLLPTD 2.22   
FLTITD+TKD 2.22 +§   
SF3B15q 1.66 +   
NPM1 1.54 +§   
RUNX1 16 1.53 + + 
NRAS 1.52 + + 
ETV6 1.48   
IDH2 1.46 +  
CBL 1.34 + + 
EZH2 1.31 + + 
U2AF1 11 1.28 +   
SRSF2 18 1.27 +#  + 
DNMT3A 19 1.25 +  
ASXL1 30 1.24 + + 
KRAS 1.22  + 
SF3B1α 28 0.92 + + 
STAG2    +∗∗  
RAD21    + 

Adjusted hazard ratio via Cox regression for the risk of leukemic transformation or death, adjusted for age, sex, and secondary/therapy-related vs primary MDSs. Mutations were also used for OS and generated 6 risk categories defining the IPSS-M: https://mds-riskmodel.com/. SF3B15q = SF3B1 mutation with isolated del(5q) or with 1 additional aberration excluding del(7q). SF3B1α= SF3B1 mutation without comutations in BCOR, BCORL1, RUNX1, NRAS, STAG2, SRSF2, or del(5q). Residual genes (Nres), the number of mutated genes in the following list: STAG2, BCOR, BCORL1, CEBPA, ETNK1, GATA2, GNB1, IDH1, NF1, PHF6, PPM1D, PRPF8, PTPN11, SETBP1, and WT1. This variable (≤2 genes) has a hazard ratio of 1.26.

Includes all TP53 mutations ± complex karyotype.

Includes all TP53 mutations.

§

With AML-like mutations.

SF3B1 with del5q and/or ASXL1 and/or RUNX1 mutations.

Associated with del(20q) and/or chromosome 7 abnormalities.

#

Associated with TET2 or separately with ASXL1, RUNX1, IDH2, and EZH2 mutations; https://mds.itb.cnr.it/#/mds.

∗∗

Also present in the report by Bernard et al68 as a residual gene (Nres).

Close Modal

or Create an Account

Close Modal
Close Modal